<DOC>
	<DOCNO>NCT00436930</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor cell white blood cell may help body build effective immune response kill tumor cell . Colony-stimulating factor , GM-CSF , increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy together GM-CSF may effective treatment melanoma . PURPOSE : This randomized phase II trial study two different vaccine therapy regimens compare well work give together GM-CSF treat patient recurrent metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With Recurrent Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival , progression-free survival , event-free survival , failure-free survival patient metastatic melanoma treat vaccine therapy comprising irradiate autologous tumor cell vs autologous dendritic cell load irradiated autologous tumor cell combination sargramostim ( GM-CSF ) . - Compare frequency immune response base delayed-type hypersensitivity irradiate autologous tumor cell serologic cellular assay baseline completion autologous tumor cell-based vaccine therapy patient . - Compare safety regimens patient . OUTLINE : This randomize study . Patients stratify accord measurable disease ( yes v ) location disease ( distant v regional ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irradiate autologous tumor cell subcutaneously ( SC ) sargramostim ( GM-CSF ) SC weekly 3 week monthly 5 month absence disease progression unacceptable toxicity . - Arm II : Patients receive autologous dendritic cell load irradiated autologous tumor cell SC GM-CSF SC weekly 3 week monthly 5 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma Regionally recurrent distant metastatic disease Must establish continuously proliferate cell line expand 200 million cell free stromal cell contamination No active CNS metastases Prior treatment brain metastasis spinal cord compression allow No clear evidence disease progression CNS No concurrent pharmacologic dose corticosteroid PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % OR ECOG PS 01 Platelet count &gt; 100,000/mmÂ³ Hematocrit &gt; 30 % Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 2.0 mg/dL Albumin &gt; 3.0 mg/dL No significant hepatic renal dysfunction No invasive cancer within past 5 year No active infection active medical condition could eminently life threatening , include follow : Active blood clot Bleeding diathesis No ongoing transfusion requirement No underlying cardiac disease associate know myocardial dysfunction No unstable angina relate atherosclerotic cardiovascular disease No know autoimmune disease Negative pregnancy test PRIOR CONCURRENT THERAPY : Prior surgery , radiotherapy , chemotherapy , biological therapy ( include sargramostim [ GMCSF ] ) , vaccine therapy allow No concurrent anticancer therapy ( e.g. , hormone therapy prostate breast cancer ) No concurrent digoxin medication treatment heart failure No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>